Why the study?
Does combined inhibition of PAR4 and PI3K/P2Y12 pathways reduce the stability of thrombin-induced platelet aggregation in human platelets?
Population
Human platelets
Comparison
Inhibition of PAR4 and/or PI3K and/or P2Y12 vs Control
Design
Preclinical
Authors
Loading...
May support dual antithrombotic targeting; hypothesis-generating in animal models and leaves open human translation.
Does combined inhibition of PAR4 and PI3K/P2Y12 pathways reduce the stability of thrombin-induced platelet aggregation in human platelets?
PAR4 acts in parallel with the P2Y12/PI3K pathway to stabilize platelet aggregates, suggesting that dual inhibition may be a potential strategy for antithrombotic therapy.
Wu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: